文献速递消化系统肿瘤

帕尼单抗联合伊立替康对比西妥昔单抗联合伊立替康治疗KRAS野生型难治性转移性结直肠癌的随机II期研究

Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
PubMed 文献 · Eur J Cancer · 2020-06-08

本研究为随机II期研究,纳入121例KRAS外显子2野生型、对氟嘧啶类、伊立替康和奥沙利铂耐药的转移性结直肠癌患者,1:1随机接受帕尼单抗联合伊立替康或西妥昔单抗联合伊立替康治疗。主要终点无进展生存期在帕尼单抗组为5.42个月,西妥昔单抗组为4.27个月(HR=0.64,95%CI 0.44-0.94),非劣效性检验P<0.001;总生存期分别为14.85个月和11.53个月(HR=0.66,95%CI 0.44-1.00,优效性P=0.050)。帕尼单抗组3/4级低镁血症发生率高于西妥昔单抗组(17% vs 7%)。

要点

  • 帕尼单抗联合伊立替康在PFS上非劣于西妥昔单抗联合伊立替康。
  • 帕尼单抗组中位PFS 5.42个月,西妥昔单抗组4.27个月(HR=0.64)。
  • 帕尼单抗组3/4级低镁血症发生率17%,高于西妥昔单抗组的7%。

核心结论

  • 在伊立替康耐药的KRAS野生型转移性结直肠癌患者中,帕尼单抗联合伊立替康的生存可能非劣于西妥昔单抗联合伊立替康。

研究设计与样本

  • 随机II期研究,纳入121例KRAS外显子2野生型、既往接受氟尿嘧啶类、奥沙利铂和伊立替康治疗的转移性结直肠癌患者,1:1随机分组。

主要发现

  • 帕尼单抗组中位PFS为5.42个月,西妥昔单抗组为4.27个月(HR=0.64,95%CI 0.44-0.94,非劣效性P<0.001,优效性P=0.058)。
  • 帕尼单抗组中位OS为14.85个月,西妥昔单抗组为11.53个月(HR=0.66,95%CI 0.44-1.00,优效性P=0.050)。
  • 帕尼单抗组3/4级低镁血症发生率为17%,西妥昔单抗组为7%。

临床怎么用

  • 对于伊立替康耐药的KRAS野生型转移性结直肠癌患者,帕尼单抗联合伊立替康可作为西妥昔单抗联合伊立替康的替代选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC). However, it has remained unclear whether panitumumab is effective when combined with irinotecan. We compared efficacies of both regimens in this randomised phase II study. PATIENTS AND METHODS: Patients with wild-type KRAS exon 2 mCRC previously treated with fluorouracil-, oxaliplatin- and irinotecan-based chemotherapies were randomised (1:1) to either panitumumab plus irinotecan (panitumumab arm) or cetuximab plus irinotecan (cetuximab arm). The primary end-point was progression-free survival (PFS). The planned sample size was 120, expecting a hazard ratio (HR) of 1.0 with non-inferiority margin of 1.3 (one-sided alpha error 0.2 and power 0.7). Major secondary end-points were overall survival (OS), response rate and safety. RESULTS: From December 2011 to September 2014, 121 patients were enrolled, and 61 and 59 patients were randomised to the panitumumab and cetuximab arms, respectively (1 patient excluded). Most patients (97%) had received prior chemotherapies containing bevacizumab. The median PFS was 5.42 months in the panitumumab arm and 4.27 months in the cetuximab arm (HR = 0.64, 95% confidence interval [CI] = 0.44-0.94, P < 0.001 for non-inferiority, P = 0.058 for superiority), and median OS was 14.85 and 11.53 months (HR = 0.66, 95% CI = 0.44-1.00, P = 0.050 for superiority), respectively. The incidence of grade 3 or 4 hypomagnesaemia was higher in the panitumumab arm than that in the cetuximab arm (17% vs. 7%). CONCLUSION: Panitumumab may be non-inferior to cetuximab in combination with irinotecan in survival of patients with irinotecan-refractory mCRC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sakai D, Taniguchi H, Sugimoto N, et al. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). Eur J Cancer. 2020. PMID: 32526634. doi:10.1016/j.ejca.2020.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。